Last $301.35 USD
Change Today -1.95 / -0.64%
Volume 859.0
RHHVF On Other Exchanges
Symbol
Exchange
OTC US
OTC US
OTC US
Xetra
SIX Swiss Ex
Xetra
SIX Swiss Ex
Mexico
Frankfurt
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

roche holding ag-genusschein (RHHVF) Snapshot

Open
$301.20
Previous Close
$303.30
Day High
$301.37
Day Low
$300.25
52 Week High
02/24/14 - $340.18
52 Week Low
10/9/13 - $254.48
Market Cap
258.4B
Average Volume 10 Days
3.8K
EPS TTM
--
Shares Outstanding
702.6M
EX-Date
03/6/14
P/E TM
--
Dividend
$8.34
Dividend Yield
2.94%
Current Stock Chart for ROCHE HOLDING AG-GENUSSCHEIN (RHHVF)

roche holding ag-genusschein (RHHVF) Related Bloomberg News

View More Bloomberg News

roche holding ag-genusschein (RHHVF) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Switzerland, European Union, and internationally. It discovers, develops, and provides diagnostic and therapeutic products and services that enable patients and healthcare professionals in the detection, prevention, diagnosis, treatment, and treatment monitoring of diseases. The company provides pharmaceutical products for various therapeutic areas comprising oncology, virology, inflammation, metabolic disorders, and central nervous system. In addition, it offers a portfolio of diagnostics products, such as blood glucose meters for diabetes patients; point-of-care testing devices for use in doctors’ offices; high-throughput analyzers for hospitals and commercial diagnostic laboratories; and start-of-the-art instruments and reagents for life science research. The company has a collaboration agreement with Astrazeneca Plc to develop a plasma-based companion diagnostic test to support AZD9291, a drug candidate for treating non-small-cell lung cancer; and a collaboration agreement with AmorChem L.P. to discover novel small molecule disease-modifying therapy for the treatment of myotonic muscular dystrophy 1 or Steinert's disease. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

85,080 Employees
Last Reported Date: 01/30/14
Founded in 1896

roche holding ag-genusschein (RHHVF) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.1M
Compensation as of Fiscal Year 2013.

roche holding ag-genusschein (RHHVF) Key Developments

Roche Introduces New Fertility Test for Assessment of Ovarian Reserve for Pregnancy

Roche announced the launch of the Elecsys Anti-Müllerian Hormone (AMH) blood test, the first fully-automated AMH test for assessing a woman’s ovarian reserve. AMH is an important fertility marker used by healthcare professionals to assess ovarian reserve levels. The AMH blood test can be measured during any day of the menstrual cycle and is a superior indicator of ovarian reserve as compared to the follicle-stimulating hormone (FSH) and estradiol. In addition, the Elecsys AMH blood test produces standardized results for assessing ovarian reserve as compared with the use of ultrasound, in which the result is often dependent on the operator or clinic. The Elecsys AMH blood test will be available in all markets accepting the CE mark in Europe, Latin America, Middle East, Africa and Asia. The test is currently not available in the United States and Japan. In the future, the Elecsys AMH assay is also intended to be used in combination with the new human recombinant follicle-stimulating hormone (human rFSH) treatment currently in phase III development at Ferring Pharmaceuticals. This combination, which will make possible individualized dosing of human rFSH based on a woman’s specific AMH level, may provide an improved option for couples seeking to conceive through in vitro fertilization.

Roche Announces Availability of ACCU-CHEK(R) Aviva Expert system

Roche announced that Roche's ACCU-CHEK(R) Aviva Expert system, the first and only blood glucose meter system with a built-in insulin calculator to be approved by the U.S. Food and Drug Administration, is now available by prescription. The device represents a significant advancement in blood glucose meter technology for people with diabetes who take multiple daily insulin injections. The meter's integrated bolus calculator provides easy-to-use and reliable dose recommendations based on automated calculations, eliminating the need for manual dosing calculations and estimations. The ACCU-CHEK Aviva Expert system is indicated as an aid in the treatment of insulin-requiring diabetes. The ACCU-CHEK Aviva Expert system consists of the ACCU-CHEK Aviva Expert meter, ACCU-CHEK Aviva Plus test strips, ACCU-CHEK Aviva control solutions, and ACCU-CHEK Bolus Advisor feature. The ACCU-CHEK Aviva Expert system is intended to facilitate the optimization of glycemic control in patients who are trained in multiple daily insulin injection therapy and are under the supervision of healthcare professionals experienced in managing insulin-treated patients. The ACCU-CHEK Aviva Expert blood glucose monitoring system is intended to be used for the quantitative measurement of glucose in fresh capillary whole blood samples drawn from the fingertips. The ACCU-CHEK Aviva Expert blood glucose monitoring system is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes. The ACCU-CHEK Aviva Expert blood glucose monitoring system is intended to be used by a single person and should not be shared. The ACCU-CHEK Aviva Expert blood glucose monitoring system should not be used for the diagnosis or screening of diabetes or for neonatal use. Alternative site testing should NOT be used with the ACCU-CHEK Aviva Expert blood glucose monitoring system. The ACCU-CHEK Aviva Expert system is intended for prescription home use only. The ACCU-CHEK Aviva Expert meter is also indicated for the calculation of an insulin dose or carbohydrate intake based on user-entered data. The ACCU-CHEK Bolus Advisor, as a component of the ACCU-CHEK Aviva Expert meter, is intended for use in providing insulin dose recommendations in response to blood glucose, health events, and carbohydrate input. The ACCU-CHEK Bolus Advisor is intended to provide direction for insulin adjustment within the scope of a pre-planned treatment program from a healthcare professional. Before patient use, a healthcare professional must prescribe the ACCU-CHEK Aviva Expert system and provide the patient-specific target blood glucose, insulin-to-carbohydrate ratio, and insulin sensitivity parameters to be programmed into the ACCU-CHEK Bolus Advisor. Once programmed, a patient must consult with the healthcare professional before making any changes to these ACCU-CHEK Bolus Advisor settings.

Roche Commences Phase III Trials for Investigational Geographic Atrophy Drug Lampalizumab

Roche announced that it has commenced Phase III trials of lampalizumab, a candidate drug for the treatment of geographic atrophy (GA). The Phase III programme will be assessing the safety and efficacy of lampalizumab as well as the drug's potential for slowing GA progression. Additionally, the studies will investigate whether lampalizumab treatment could potentially be more beneficial for people with a mutation in complement factor I, a genetic biomarker. The initiation on the Phase III programme comes after the company announced positive results from the Phase II MAHALO studies in 2013. The Phase II study, which met its primary endpoint, showed that lampalizumab was associated with a 20.4% reduction rate in the area of GA at 18 months. GA is an advanced form of age-related macular degeneration (AMD), affecting more than five million people globally. The Phase III studies - Chroma (GX29176) and Spectri (GX29185) - are identically designed, double-masked, randomised studies, each including 936 patients, evaluating lampalizumab 10mg administered every four or six weeks by intravitreal injection in comparison to sham injections. The primary aim of the trials is to show a reduction in the rate of GA disease progression.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHHVF:US $301.35 USD -1.95

RHHVF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $26.29 USD +0.08
Gilead Sciences Inc $105.96 USD +0.03
Merck & Co Inc $60.49 USD +0.18
Novartis AG SFr.88.30 CHF -0.15
Pfizer Inc $30.40 USD -0.18
View Industry Companies
 

Industry Analysis

RHHVF

Industry Average

Valuation RHHVF Industry Range
Price/Earnings 21.4x
Price/Sales 4.6x
Price/Book 13.0x
Price/Cash Flow 17.4x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDING AG-GENUSSCHEIN, please visit www.roche.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.